BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Allergan Inc. (AGN) Faces Generic Competition for Restasis Eye Drug


6/26/2013 7:53:54 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A spate of downgrades and price-target reductions for Allergan Inc. sent shares tumbling at a far greater pace than the rest of the struggling market on Monday, with the pharmaceutical firm’s stock dropping more than 10% at one point on concerns over generic challenges to its dry-eye drug Restasis. Allergan shares were off more than 9% at $83.77 in recent action as the U.S. Food and Drug Administration seemed to pave the way for competitors to come in and start marketing generic forms of Restasis within a year or two. The FDA released guidance for developing generic forms of Restasis late Friday, saying that a clinical trial would not be necessary, even though Allergan insists it is. That could get a generic to market much faster than expected, analysts say, and take a bite out of earnings in future years. Restasis is Allergan’s second-best selling drug, behind Botox.

Help employers find you! Check out all the jobs and post your resume.


Read at Market Watch

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES